D.A. Wallach

D.A. Wallach, co-founder of Time BioVentures and former lead singer of Chester French, shares his unique journey from music to biotech investing. He discusses the complexities of biotech, comparing it to a 'bag of options' with long timelines. Wallach emphasizes the importance of experienced founders and the challenges of clinical trials as major bottlenecks. He also tackles the impact of AI on drug discovery, the rise of China's biotech sector, and the nuances of patient autonomy, all while hinting at how music and biotech intersect.

D.A. Wallach, a General Partner at Time BioVentures, focuses on biotech and machine learning. Matt Turck from FirstMark specializes in enterprise software and AI. Astasia Myers of Felicis invests in early-stage AI and cybersecurity. They discuss the biotech sector's struggle amidst a tough market, contrasting it with the booming AI landscape. Virtual doctors and advancements in fertility tech have the potential to revolutionize healthcare. The panel also explores investment trends and the democratization of AI tools—shaping the future of startups.

D.A. Wallach, an investor, musician, and writer, shares insights on the intersection of creativity and technology. He discusses engineered serendipity through cold emailing and the complexities of biotech investments like CRISPR. D.A. delves into the balance of market innovation and healthcare rights, highlighting AI's potential to empower patients. He reflects on the role of beauty in art and urges artists to reclaim their influence. With his diverse experiences, D.A. inspires listeners to embrace curiosity and interdisciplinary collaboration.

D.A. Wallach, venture investor at Time BioVentures and biotech-focused entrepreneur-artist. Dan Rasmussen, founder of Verdad Advisers and deep-equity researcher on biotech. They discuss biotech’s recent surge and research-driven lenses on winners and valuation. They cover China’s biotech rise, shifting IPO and VC dynamics, US stock valuation debates, and Japan’s corporate reform story.

D.A. Wallach, former lead singer of Chester French and artist-in-residence at Spotify, shares his journey from music to healthcare investing. He discusses how advancements in personalized medicine and genetic therapies are revolutionizing treatment options. Wallach dives into the potential of CRISPR technology and the ethics surrounding gene editing, as well as the complexities of drug pricing in today's healthcare system. He emphasizes the importance of informed choices in healthcare investments and the transformative role of technology in personal health.

D.A. Wallach, venture capitalist and co-founder of Time BioVentures who invests at the intersection of biotech and tech. He explains valuing development-stage drug companies as portfolios of options. Topics include why specialists can still earn alpha, how base rates and interest rates shape biotech valuations, AI’s incremental role in drug discovery, and portfolio construction for high-uncertainty investments.

In this episode, Dan Rasmussen, founder of Verdad Advisers, and D.A. Wallach, a venture investor and musician, dive into the exciting world of biotech and healthcare. They discuss the transformative impact of AI and emerging treatments like gene therapy on patient care. The duo shares insights on private equity dynamics and investment strategies, especially in the context of rising interest rates. They also touch on global market trends and Japan's corporate reforms, highlighting unique investment opportunities in the evolving landscape.

D.A. Wallach, a venture capitalist at Time BioVentures and former frontman of Chester French, dives into the murky waters of healthcare ethics. He draws fascinating parallels between music and medicine, questioning outdated titles like 'doctor' and advocating for AI's role in patient care. With a focus on the need for a universal, evidence-based standard of care, he critiques the current profit-driven systems and urges a reevaluation of healthcare relationships. Wallach's insights promise a provocative peek into a future where compassion meets innovation.

Chris Rizik, investor at Renaissance Venture Capital, on building in-house platforms and company-creation in biopharma. D.A. Wallach, general partner at Time BioVentures, praises a founder’s rapid responsiveness and focus. Casber Wang, investor at Sapphire Ventures, recounts Kyle Hanselman’s evolution scaling SMB cybersecurity through MSP distribution and team reshuffles. They focus on visionary leadership, platform leverage, founder adaptability, and market timing.

D.A. Wallach, co-founder of Time BioVentures and former recording artist, shares his intriguing journey from touring with stars like Lady Gaga to investing in life sciences. He discusses how his experiences in the music industry shaped his investment philosophy. The conversation covers the intersection of creativity and technology, tackling healthcare reform, and the role of AI in drug discovery. Wallach emphasizes the importance of taste in investment decisions, highlighting the need for innovation within the healthcare system.